Adipokines as a link between obesity and chronic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 305, Issue 12, 2013, Pages

  Briffa, Jessica F ^a,c   Mcainch, Andrew J ^a   Poronnik, Philip ^b   Hryciw, Deanne H ^c  

^a VICTORIA UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adipokines; Adiponectin; Chronic kidney disease; Leptin; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN;

ADIPOCYTE; ADIPOSE TISSUE; ALBUMINURIA; BODY WEIGHT; CELL MEMBRANE PERMEABILITY; CELL TYPE; CHRONIC KIDNEY DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; GLOMERULOSCLEROSIS; GLOMERULUS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLEPTINEMIA; HYPERTENSION; HYPOADIPONECTINEMIA; IN VITRO STUDY; INTRACELLULAR SIGNALING; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY DISTAL TUBULE; KIDNEY FAILURE; KIDNEY HYPERTROPHY; KIDNEY PROXIMAL TUBULE; MACULA DENSA; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; URINARY EXCRETION; URINE VOLUME;

ADIPOKINES; ADIPONECTIN; CHRONIC KIDNEY DISEASE; KEYWORDS; LEPTIN; OBESITY;

ADIPOCYTES; ADIPOKINES; ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; HUMANS; OBESITY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84890324182     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00263.2013     Document Type: Review

References (82)

1. Ahima R. Linking adiponectin to proteinuria. J Clin Invest 118: 1619-1622, 2008.
2. Aneja A, El-Atat F, McFarlane S, Sowers J. Hypertension and obesity. Recent Prog Horm Res 59: 169-205, 2004.
3. Attoub S, Noe V, Pirola L, Bruyneel E, Chastre E, Mareel M, Wymann M, Gespach C. Leptin promotes invasiveness of kidney and colonic epithelia cells via phosphoinositide 3-kinase-, Rho-, and Rac-dependant signaling pathways. FASEB J 14: 2329-2338, 2000.
4. Axelsson J, Bergsten A, Qureshi A, Heimbürger O, Bárány P, Lön-nqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 69: 596-604, 2006.
5. Balistreri C, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm 2010: 802078, 2010.
6. Banks A, Davis S, Bates S, Myers M. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 275: 14563-14572, 2000.
7. +-ATPase: the possible novel mechanism of leptin-induced hypertension. Pol J Pharmacol 56: 213-222, 2004.
8. +-ATPase activity in the rat-impaired effect in dietary-induced obesity. Med Sci Monit 8: BR221-BR229, 2002.
9. Bełtowski J, Wójcicka G, Marciniak A, Jamroz A. Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci 74: 2987-3000, 2004.
10. Bjørbaek C, Buchholz R, Davis S, Bates S, Pierroz D, Gu H, Neel B, Myers M, Flier J. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 276: 4747-4755, 2001.
11. Boini K, Zhang C, Xia M, Han W, Brimson C, Poklis J, Li P. Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochim Biophys Acta 1801: 1294-1304, 2010.
12. Briffa JF, Grinfeld E, McAinch AJ, Poronnik P, Hryciw DH. Short term exposure to elevated levels of leptin reduces proximal tubule cell metabolic activity. Mol Cell Endocrinol 382: 38-45, 2014.
13. Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ 31: 219-230, 2012.
14. Chagnac A, Herman M, Zingerman M, Erman A, Rozen-Zvi B, Hirsh J, Gafter U. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 23: 3946-3952, 2008.
15. Chen K, Hung C, Hsu H, Jing Y, Yang C, Chen J. Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-fj/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats. Chem Biol Interact 190: 45-53, 2011.
16. Chen M, Chung F, Chang D, Tsai J, Huang H, Shin S, Lee Y. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91: 295-299, 2006.
17. Cheng H, Kim M, Valerius M, Surendran K, Schuster-Gossler K, Gossler A, McMahon A, Kopan R. Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron. Development 134: 801-811, 2007.
18. Cumin F, Baum H, Levens N. Mechanism of leptin removal from the circulation by the kidney. J Endocrinol 155: 577-585, 1997.
19. Dagogo-Jack S, Ovalle F, Landt M, Gearing B, Coyne D. Hyperlep-tinemia in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 18: 34-40, 1998.
20. Declèves A, Mathew A, Cunard R, Sharma K. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol 22: 1846-1855, 2011.
21. Dhillon S, Belsham D. Leptin differentially regulates NPY secretion in hypothalamic cell lines through distinct intracellular signal transduction pathways. Regul Pept 167: 192-200, 2011.
22. Doumatey A, Zhou J, Huang H, Adeleye J, Balogun W, Fasanmade O, Johnson T, Oli J, Okafor G, Amoah A, Eghan B, Agyenim-Boateng K, Acheampong J, Adebamowo C, Adeyemo A, Rotimi C. Circulating adiponectin is associated with renal function independent of age and serum lipids in West Africans. Int J Nephrol 2012: 730920, 2012.
23. Falcão-Pires I, Castro-Chaves P, Miranda-Silva D, Lourenço A, Leite-Moreira A. Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov Today 17: 880-889, 2012.
24. Ferris M, Hogan S, Chin H, Shoham D, Gipson D, Gibson K, Yilmaz S, Falk R, Jannette J. Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study. Clin J Am Soc Nephrol 2: 1207-1214, 2007.
25. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsu-zawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430, 2005.
26. Garibotto G, Russo R, Franceschini R, Robaudo C, Saffioti S, Sofia A, Rolandi E, Deferrari G, Barreca T. Inter-organ leptin exchange in humans. Biochem Biophys Res Commun 247: 504-509, 1998.
27. Hall J. The kidney, hypertension, and obesity. Hypertension 41: 625-633, 2003.
28. Hama H, Saito A, Takeda T, Tanuma A, Xie Y, Sato K, Kazama J, Gejyo F. Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors. Endocrinology 145: 3935-3940, 2004.
29. Hocher B, Thöne-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer H, Schleuning W, Theuring F. Endothelin-1 transgenic mice develop glo-merulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 99: 1380-1389, 1997.
30. Hsu Y, Cheng C, Chen Y, Chen T, Sue Y, Tsai W, Chen C. Long-term leptin treatment exerts a pro-apoptotic effect on renal tubular cells via prostaglandin E2 augmentation. Eur J Pharmacol 689: 65-71, 2012.
31. Huang Q, Guo Y, Zeng H, Xie W, Yan H, Ding H. Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Endocr Res 36: 93-100, 2011.
32. Jackson E, Li P. Human leptin has natriuretic activity in the rat. Am J Physiol Renal Physiol 272: F333-F338, 1997.
33. Johnson D, Jones G, Mathew T, Ludlow M, Chadban S, Usherwood T, Polkinghorne K, Colagiuri S, Jerums G, Macisaac R, Martin H. Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement. Med J Aust 197: 224-225, 2012.
34. Johnson R, Segal M, Srinivas T, Ejaz A, Mu W, Roncal C, Sa'Nchez-Lozada L, Gersch M, Rodriguez-Iturbe B, Kang D, Acosta J. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol 16: 1909-1919, 2005.
35. Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving H, Vionnet N, Rossing P. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 74: 649-654, 2008.
36. Jung H, Park K, Cho Y, Chung S, Cho H, Cho S, Kim S, Kim S, Lee H, Park K. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 69: 76-85, 2006.
37. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 26: 439-451, 2005.
38. Kassab S, Kato T, Wilkins F, Chen R, Hall J, Granger J. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 25: 893-897, 1995.
39. Kershaw E, Flier J. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548-2556, 2004.
40. Kramer H, Saranathan A, Luke A, Durazo-Arvizu R, Guichan C, Hou S, Cooper R. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 17: 1453-1459, 2006.
41. Landray M, Emberson J, Blackwell L, Dasgupta T, Zakeri R, Morgan M, Ferro C, Vickery S, Ayrton P, Nair D, Dalton R, Lamb E, Baigent C, Townend J, Wheeler D. Prediction of ESRD and death among people with CKD: the chronic renal impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis 56: 1082-1094, 2010.
42. Landt M, Ludbrook P, Billadello J. Role of protein binding in renal elimination of leptin. Clin Endocrinol (Oxf) 59: 44-48, 2003.
43. Lang K, Ratke J. Leptin and adiponectin: new players in the field of tumor cell and leukocyte migration. Cell Commun Signal 7: 27, 2009.
44. Lee M, Madani S, Sekula D, Sweeney G. Leptin increases expression and activity of matrix metalloproteinase-2 and does not alter collagen production in rat glomerular mesangial cells. Endocr Res 31: 27-37, 2005.
45. Lee M, Orlov D, Sweeney G. Leptin induces rat glomerular mesangial cell hypertrophy, but does not regulate hyperplasia or apoptosis. Int J Obes 29: 1395-1401, 2005.
46. Levey A, Coresh J, Balk E, Kausz A, Levin A, Steffes M, Hogg R, Perrone R, Lau J, Eknoyan G. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139: 137-147, 2003.
47. Lönnqvist F, Nordfors L, Jansson M, Thörne A, Schalling M, Arner P. Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest 99: 2398-2404, 1997.
48. Maffei M, Halaas J, Ravussin E, Pratley R, Lee G, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern P, Friedman J. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 11: 1155-1161, 1995.
49. Maggio A, Wacker J, Montecucco F, Galan K, Pelli G, Mach F, Beghetti M, Farpour-Lambert N. Serum resistin and inflammatory and endothelial activation markers in obese adolescents. J Pediatr 161: 1022-1027, 2012.
50. Malyszko J, Malyszko J, Mysliwiec M. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney al-lograft recipients. Transplant Proc 41: 150-153, 2009.
51. Marshansky V, Ausiello D, Brown D. Physiological importance of endosomal acidification: potential role in proximal tubulopathies. Curr Opin Nephrol Hypertens 11: 527-537, 2002.
52. Martinez Cantarin M, Waldman S, Doria C, Frank A, Maley W, Ramirez C, Keith S, Falkner B. The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int 83: 487-494, 2013.
53. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira A, Beck G, Kusek J, Collins A, Levey A, Sarnak M. Adiponec-tin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17: 2599-2606, 2006.
54. Menzaghi C, Salvemini L, Fini G, Thompson R, Mangiacotti D, Di Paola R, Morini E, Giorelli M, De Bonis C, De Cosmo S, Doria A, Trischitta V. Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. PLoS One 7: e38414, 2012.
55. Merabet E, Dagogo-Jack S, Coyne D, Klein S, Santiago J, Hmiel S, Landt M. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 82: 847-850, 1997.
56. Meyer C, Robson D, Rackovsky N, Nadkarni V, Gerich J. Role of the kidney in human leptin metabolism. Am J Physiol Endocrinol Metab 273: E903-E907, 1997.
57. Montani J, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes 26: S28-S38, 2002.
58. Ortiz P, Garvin J. Role of nitric oxide in the regulation of nephron transport. Am J Physiol Renal Physiol 282: F777-F784, 2002.
59. Patel S, Rajala M, Rossetti L, Scherer P, Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science 304: 1154-1158, 2004.
60. Persson P, Hansell P, Palm F. Tubular reabsorption and diabetes-induced glomerular hyperfiltration. Acta Physiol (Oxf) 200: 3-10, 2010.
61. Plantinga L, Crews D, Coresh J, Miller E, Saran R, Yee J, Hedgeman E, Pavkov M, Eberhardt M, Williams D, Powe N. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 5: 673-682, 2010.
62. Richter C. Role of endothelin in chronic renal failure-developments in renal involvement. Rheumatology (Oxford) 45: iii36-iii38, 2006.
63. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 64: 355-365, 2006.
64. Saito A, Takeda T, Hama H, Oyama Y, Hosaka K, Tanuma A, Kaseda R, Ueno M, Nishi S, Ogasawara S, Gondaira F, Suzuki Y, Gejyo F. Role of megalin, a proximal tubular endocytic receptor, in the pathogen-esis of diabetic and metabolic syndrome-related nephropathies: protein metabolic overload hypothesis. Nephrology (Carlton) 10, Suppl: S26-S31, 2005.
65. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14: 1431-1437, 1994.
66. Shah M, Baterina OJ, Taupin V, Farquhar M. ARH directs megalin to the endocytic recycling compartment to regulate its proteolysis and gene expression. J Cell Biol 202: 113-127, 2013.
67. Sharma K, Considine R, Michael B, Dunn S, Weisberg L, Kurnik B, Kurnik P, O'Connor J, Sinha M, Caro J. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 51: 1980-1985, 1997.
68. Sharma K, Ramachandrarao S, Qui G, Usui H, Zhu Y, Dunn S, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B, Goldstein B. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118: 1645-1656, 2008.
69. Shen Y, Hughes J, Charlesworth J, Kelly J, Peake P. Adiponectin is present in the urine in its native conformation, and specifically reduces the secretion of MCP-1 by proximal tubular cells. Nephrology (Carlton) 13: 405-410, 2008.
70. Simonds S, Cowley M, Enriori P. Leptin increasing sympathetic nerve outflow in obesity: a cure for obesity or a potential contributor to metabolic syndrome? Adipocyte 1: 177-181, 2012.
71. Song H, Lee M, Kim B, Park Y, Ko G, Kang Y, Han J, Han S, Han K, Kim H, Cha D. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 295: F1485-F1494, 2008.
72. Stastny J, Bienertova-Vasku J, Vasku A. Visfatin and its role in obesity development. Diabetes Metab Syndr 6: 120-124, 2012.
73. Takeyama A, Sato H, Soma-Nagae T, Kabasawa H, Suzuki A, Yamamoto-Kabasawa K, Hosojima M, Kaneko R, Higuchi F, Kaseda R, Ogasawara S, Narita I, Saito A. Megalin is downregulated via LPS-TNF-a-ERK1/2 signaling pathway in proximal tubule cells. Biochem Biophys Res Commun 407: 108-112, 2011.
74. Vecchione C, Maffei A, Colella S, Aretini A, Poulet R, Frati G, Gentile M, Fratta L, Trimarco V, Trimarco B, Lembo G. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 51: 168-173, 2002.
75. Verma S, Li S, Wang C, Fedak P, Li R, Weisel R, Mickle D. Resistin promotes endothelial cell activation: further evidence of adipokine-endo-thelial interaction. Circulation 108: 736-740, 2003.
76. von Eynatten M, Liu D, Hock C, Oikonomou D, Baumann M, Allolio B, Korosoglou G, Morcos M, Campean V, Amann K, Lutz J, Hee-mann U, Nawroth P, Bierhaus A, Humpert P. Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes 58: 2093-2099, 2009.
77. Wohlfarth V, Drumm K, Mildenberger S, Freudinger R, Gekle M. Protein uptake disturbs collagen homeostasis in proximal tubule-derived cells. Kidney Int Suppl: S103-S109, 2003.
78. Wolf G, Hamann A, Han D, Helmchen U, Thaiss F, Ziyadeh F, Stahl R. Leptin stimulates proliferation of TGF-(3 expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 56: 860-872, 1999.
79. Wolf G, Schroeder R, Ziyadeh F, Stahl R. Albumin up-regulates the type II transforming growth factor-(3 receptor in cultured proximal tubular cells. Kidney Int 66: 1849-1858, 2004.
80. Yang R, Barouch L. Leptin signaling and obesity: cardiovascular consequences. Circ Res 101: 545-559, 2007.
81. Yaturu S, Reddy R, Rains J, Jain S. Plasma and urine levels of resistin and adiponectin in chronic kidney disease. Cytokine 37: 1-5, 2007.
82. Zou Z, Chung B, Nguyen T, Mentone S, Thomson B, Biemesderfer D. Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule. J Biol Chem 279: 34302-34310, 2004.